Features | Partner Sites | Information | LinkXpress
Sign In
Bio-Rad Diabetes Division
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Gene Linked to Poor Prognosis for Melanoma

By Labmedica International staff writers
Posted on 06 Mar 2013
A gene has been identified that is present in some patients with melanoma, which appears to make the tumor cells more resistant to treatment.

The gene, Tumor protein p63 (TP63), is unexpectedly expressed in a number of melanoma cases and correlates significantly with a worse prognosis and it is hoped this new understanding of what makes some melanoma cells so difficult to kill will help the development of new therapies.

Scientists at Queen Mary, University of London (UK) analyzed 156 melanoma tissue samples from 129 individuals for expression of the protein p63, which is encoded by the gene TP63. Overall, 19 recurrent melanoma samples and 56 metastatic melanoma tumor samples from 49 individuals, 22 males and 27 females, were analyzed. The median age at diagnosis was 60.6 years and the median follow up for this cohort was 1.52 years. The proportion of p63-positive tumors comprised 10/19 (53%) of recurrent tumors and 37/56 (66%) of metastatic tumors.

Overall mortality for recurrent and metastatic tumors was 45% and melanoma-specific mortality was 37%. Median age of death was 62.4 years with median time to death from first recurrence or metastases was 15 months. The number of cases of melanoma is rising faster than almost any other cancer and one of the main risk factors is ultraviolet light, which comes from the sun or sun beds [tanning bed]. While early-stage melanomas can often be removed by surgery, more advanced melanomas are much harder to treat.

Daniele Bergamaschi, PhD, a senior lecturer in cutaneous research at Queen Mary said, "For most patients where the melanoma has spread beyond the skin, there are few effective treatments and overall survival rates for this disease have not changed much over the past 30 years. To develop better treatments we need to understand the basic biology underpinning why these cells are so resistant to being killed."

Dr. Bergamaschi added, "We did not expect to find the TP63 gene expressed in melanoma. It is not usually found in the melanocytes (skin pigment cells), which are the cells from which melanomas develop. However, it appears in some cases this gene is turned on as the tumor forms, and when it does it is linked to a worse prognosis." The study was published on February 18, 2013, in the Journal of Experimental Medicine.

Related Links:
Queen Mary, University of London



77 ELEKTRONIKA
DiagCor Bioscience
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.